The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Celgene; Idera; Immunogen; Janssen; Seagen
Speakers' Bureau - Gilead Sciences; Seagen
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen (Inst); Molecular Templates (Inst); Seagen (Inst)
 
Hailun Li
No Relationships to Disclose
 
Brad S. Kahl
Consulting or Advisory Role - Seagen
 
Michael J. Robertson
No Relationships to Disclose
 
Jonathan Cohen
Consulting or Advisory Role - Millennium; Pharmacyclics; Seagen
 
Ranjana H. Advani
Honoraria - Eisai; GE Healthcare; Millennium
Research Funding - Agensys (Inst); Allos Therapeutics (Inst); Celgene (Inst); Genentech/Roche (Inst); Idera (Inst); Janssen (Inst); Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen
 
Richard Ambinder
No Relationships to Disclose
 
Timothy S. Fenske
Honoraria - Seagen
Consulting or Advisory Role - Seagen
 
Stephen Maxted Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Seagen (Inst)